Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

toothbrush

- PMLiVE

Eli Lilly’s Jaypirca recommended by CHMP to treat chronic lymphocytic leukaemia

Approximately 100,000 new cases of the disease are diagnosed globally every year

regeneron headquarters

Regeneron receives positive CHMP opinion for linvoseltamab in multiple myeloma

More than 35,000 new cases of the blood cancer are diagnosed every year in Europe

- PMLiVE

Healthcare communications

Using impact to show accountability and progress

- PMLiVE

The Only Way We Can Go is Up: Improving Screening and Management of Female Cancers

One of the toughest challenges of educating many African women about female cancers and disease prevention is overcoming cultural biases, as well as shame, stigma, and misinformation. Here’s how two...

Medscape Education

- PMLiVE

Moderna’s RSV vaccine mRESVIA granted MHRA approval to protect older adults

RSV is responsible for 14,000 hospitalisations per year in UK adults aged 65 years and older

- PMLiVE

Roche’s Genentech granted FDA approval for TNKase in acute ischaemic stroke

TNKase is the first stroke medicine to be approved by the regulator in almost three decades

- PMLiVE

BeiGene’s Tevimbra approved by FDA for first-line oesophageal cancer use

Oesophageal squamous cell carcinoma accounts for nearly 90% of all oesophageal cancers

- PMLiVE

Luto expands to Switzerland with new office

The Basel office places the company at the heart of Europe’s life sciences sector

- PMLiVE

Setting your sights – the marketing objectives that guide everything that follows

Strong brands need clear objectives – the four steps to avoiding wombat marketing

- PMLiVE

J&J receives three CHMP recommendations for immunology and oncology indications

Tremfya, Stelara and Darzalex have been recommended for ulcerative colitis, Crohn’s disease and multiple myeloma, respectively

- PMLiVE

Sobi receives NICE recommendation for Altuvoct in severe haemophilia A

Approximately 7,700 people in England are living with the genetic bleeding disorder

- PMLiVE

MHRA approves Galderma’s Nemluvio to treat atopic dermatitis and prurigo nodularis

The drug has been authorised to treat patients with moderate-to-severe cases of the skin diseases

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links